ABCL

AbCellera Biologics Inc.

ABCL · CIK 1703057 · Annual (10-K) · Last 5 years

Financial Trends

Revenue$75M
20212025
Net Income−$146M
20212025
Operating CF−$131M
20212025
Free Cash Flow−$174M
20212025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕
Revenue$0.1B$0.0B$0.0B$0.5B$0.4B
Cost of Revenue—————
Gross Profit—————
R&D Expense$0.2B$0.2B$0.2B$0.1B$0.1B
SG&A Expense—————
Operating Income$-0.2B$-0.3B$-0.2B$0.2B$0.2B
Net Income$-0.1B$-0.2B$-0.1B$0.2B$0.2B
EPS (Basic)$-0.49$-0.55$-0.51$0.56$0.56
EPS (Diluted)$-0.49$-0.55$-0.51$0.50$0.48

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕
Total Assets$1.4B$1.4B$1.5B$1.5B$1.3B
Current Assets$0.7B$0.8B$0.9B$1.0B$0.9B
Cash & Equivalents$0.1B$0.2B$0.1B$0.4B$0.5B
Total Liabilities$0.4B$0.3B$0.3B$0.3B$0.3B
Current Liabilities$0.1B$0.1B$0.1B$0.1B$0.1B
Stockholders' Equity$1.0B$1.1B$1.2B$1.2B$1.0B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕
Operating Cash Flow$-0.1B$-0.1B$-0.0B$0.3B$0.2B
Investing Cash Flow$0.1B$0.1B$-0.2B$-0.4B$-0.3B
Capital Expenditures$0.0B$0.1B$0.1B$0.1B$0.1B
Financing Cash Flow$0.0B$0.0B$0.0B$-0.0B$-0.0B
← Companies